Video
Elizabeth A. Thiele, MD, PhD
Dr. Thiele describes a study of cannabidiol in children with Lennox-Gastaut syndrome.
Video
Justin Gover
Justin Gover, Chief Executive Officer of Greenwich Biosciences, discusses the FDA's planned review of Epidiolex, a formulation of cannabidiol, for the treatment of Dravet syndrome and Lennox-Gastaut syndrome.
Recommended Reading
Related Articles
-
-
Conference Coverage
Cannabidiol Reduces Drop Seizures in Patients With Lennox-Gastaut Syndrome
BOSTON―Cannabidiol (CBD) as an add-on therapy may reduce drop seizures by 50% in some adults and children with Lennox-Gastaut...
Conference Coverage
-
Novel Treatment Options for Epilepsy -
‘Compelling’ Results for AI EEG to Predict Functional Outcomes -
With Proper Training, AI Can Be a Useful Tool in Epilepsy Management -
Genetic Testing Is Recommended for Adult Patients With Epilepsy -
Alzheimer’s and Epilepsy: Can Shared Molecular Mechanisms Reveal New Opportunities for Epilepsy? -
Despite Few CNS Gene Therapies for Epilepsy, New Research Offers Hope -
Poverty tied to poor cognition in patients with epilepsy -
Genetic testing warranted in epilepsy of unknown origin -
Sleep disorders linked to increased mortality risk in epilepsy -
Noninvasive testing in midlife flags late-onset epilepsy risk
Literature Review
-
Can Antihistamines Trigger Seizures in Young Kids? -
-
-
-
-
Epilepsy Linked to Higher COVID Hospitalization, Death Rates -
Service Dogs Lead to Fewer Seizures in Treatment-Resistant Epilepsy -
Seizure Risk Is Nearly Double in Patients With MS -
New, Updated Guidelines for Comprehensive Epilepsy Care -
Question 1 of 5